| | 739-71-9 Basic information More.. |
| Product Name: | TRIMIPRAMINE | | Synonyms: | 2’-metil-3’-dimetilamino-propil-5-iminodibenzile;2'-Metil-3'-dimetilamino-propil-5-iminodibenzile;3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N,2-trimethyl-1-propanamine;5-(3-(Dimethylamino)-2-methylpropyl)-10,11-dihydro-5H-dibenz(b,f)azepine;5-(gamma-dimethylamino-beta-methylpropyl)-10,11-dihydro-5h-dibenzo(b,f)azepi;5-(gamma-Dimethylamino-beta-methylpropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine;5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(dimethylamino)-2-methylpropyl)-;5H-Dibenz[b,f]azepine, 5-[3-(dimethylamino)-2-methylpropyl]-10,11-dihydro- | | CAS: | 739-71-9 | | MF: | C20H26N2 | | MW: | 294.43 | | EINECS: | 212-008-3 | | Mol File: | 739-71-9.mol |  |
Use
Trimipramine, a tricyclic antidepressant was introduced in 1961
for the management of endogenous depression. Much of the adverse effects are
caused by its antimuscarinic actions. These include dry mouth, cardiac
arrhythmias, central nervous system disturbances, blood disorders and risk of
suicide. The risk of suicide and dangers related to overdosage led Norwegian
Medicines Control Authority to put the higher strength formulation under
prescribing restriction in 1992. The risk of death following overdosage is
apparently higher for products containing tricyclic compounds as compared with
nontricyclic products.
|
|
739-71-9
Recommend Suppliers |
|